SuperGen PIM Kinase Presentations at AACR
31 Marzo 2011 - 12:00PM
Business Wire
SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated
to the discovery and development of novel cancer therapies, today
announced the acceptance of three abstracts from the SuperGen PIM
kinase inhibitor program. Poster presentations by SuperGen and
collaborators will occur on April 3 and 5, 2011 at the American
Association for Cancer Research (AACR) 102nd Annual Meeting in
Orlando, Florida.
The posters will present pre-clinical data on the role played by
PIM kinases and their pharmacological inhibition in multiple
oncology indications. Copies of the posters will be made available
for viewing in the Pipeline section of the Company’s website
www.supergen.com following the respective presentations.
Targeting Pim kinases by SGI-1776 in mantle cell
lymphoma
Abstract 586, Poster Section 25, Poster Board 10
Poster Presentation: Sunday, April 3, 1 – 5 pm ET
The serine/threonine kinase Pim-1 promotes drug resistance
mediated by the ATP-binding cassette multidrug resistance protein
breast cancer resistance protein (BCRP, ABCG2) by stabilizing
higher-order BCRP multimers
Abstract 706, Poster Section 29, Poster Board 20
Poster Presentation: Sunday, April 3, 1 – 5 pm ET
PIM kinase inhibition blocks activation of mTOR pathway
components and enhances rapamycin-mediated tumor growth inhibition
in prostate cancers
Abstract 2915, Poster Section 3, Poster Board 8
Poster Presentation: Tuesday, April 5, 8 am – 12 pm ET
About SuperGen
SuperGen is a pharmaceutical company dedicated to the discovery
and development of novel cancer therapeutics in epigenetic and cell
signaling modulation. The Company develops products through
biochemical and clinical proof of concept to partner for further
development and commercialization. For more information about
SuperGen, please visit http://www.supergen.com.
Grafico Azioni Supergen, Inc. (MM) (NASDAQ:SUPG)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Supergen, Inc. (MM) (NASDAQ:SUPG)
Storico
Da Giu 2023 a Giu 2024